| Document |
Document Title |
|
WO/2017/099475A1 |
The present invention relates to a peptide derivative having two or more amino acids linked to each other, a method for preparing the peptide derivative, and a feed additive and feed composition comprising the peptide derivative. The pep...
|
|
WO/2017/092083A1 |
Disclosed are a DPP-4 inhibitor compound, a polymer and a preparation method and use. The structure of said compound is X-R1-R2-Y, X and Y respectively being a group formed of a DPP-4 inhibitor or a DPP-4 inhibitor analogue containing an...
|
|
WO/2017/094023A1 |
In accordance with the present subject matter there is provided a process for separating hydrophobic material from a mixture of hydrophobic and hydrophilic material using peptide-based amphiphilic organogelators.
|
|
WO/2017/093482A1 |
The present invention relates to a method for increasing the activity and/or the yield of a recombinant vitamin K-dependent protein expressed in cell culture. The present invention further relates to uses and compositions of matter.
|
|
WO/2017/096311A1 |
Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characte...
|
|
WO/2017/093897A1 |
Compositions comprising an antioxidant directed or indirectly conjugated to an aromatic-cationic peptide are provide. Said antioxidants are selected from TEMPO, Tro, PBN, AHDP, DBHP, Caf and Hem and may be conjugated to the aromatic-cati...
|
|
WO/2017/096036A1 |
The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or...
|
|
WO/2017/085034A1 |
New gelatinase inhibitors, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and/or prophylaxis of conditions wherein inhibition of gelatinases is useful such as epilepsy, schizophreni...
|
|
WO/2017/087034A1 |
Peptides, topical compositions, and methods of improving health and/or appearance of human integuments, such as keratinous surfaces and fibers are provided. The peptides have from 3-12 amino acid residues and comprise the sequence YNT (S...
|
|
WO/2017/086303A1 |
The purpose of the present invention is to provide a peptide composition that includes a functional peptide. The present invention provides a peptide composition that includes one or more components selected from the group consisting of:...
|
|
WO/2017/079832A1 |
The disclosure pertains to C-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
|
|
WO/2017/079831A1 |
The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
|
|
WO/2017/079835A1 |
The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
|
|
WO/2017/079833A1 |
The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
|
|
WO/2017/082620A1 |
The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound containing the same, and a pharmaceutical composition containing the same as an active ingredient...
|
|
WO/2017/079834A1 |
The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
|
|
WO/2017/079391A1 |
The present invention provides compounds of Formula I and Formula II, and related compositions and methods.
|
|
WO/2017/079262A1 |
The present invention provides compositions and methods for providing controllable local delivery of a conjugate of bortezomib (Btz) and a bisphosphonate to promote bone formation. In certain embodiments, the invention is used as a treat...
|
|
WO/2017/072062A1 |
The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the c...
|
|
WO/2008/076904A9 |
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.
|
|
WO/2017/062990A1 |
A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or ...
|
|
WO/2017/060533A1 |
The subject matter of the present invention concerns a novel family of peptide conjugates of formula (I): A-X1-X2-Pro-Ala-X-B in which: - A is a hydrogen atom, a C6 to C20 acyl group or a cholesterol residue; - X1 is a covalent bond, an ...
|
|
WO/2017/058808A1 |
Disclosed are compounds based on dolastatins, drug-conjugates, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharaceutical compositions and methods of treatment. The compounds and drug-conjugates disclosed he...
|
|
WO/2017/054080A1 |
Compounds of general formula (I) having cytotoxic and/or anti-mitotic activity and methods of using such compounds, as well as pharmaceutical compositions comprising such compounds. The compounds may also be conjugated with a targeting m...
|
|
WO/2017/050854A1 |
The present invention relates to the use of a cyclic peptide comprising the tripeptide reproducing a binding site of fertilin beta to the oocyte integrin, for improving cellular energy metabolism. More particularly, the invention concern...
|
|
WO/2017/053864A1 |
The invention provides compounds and compositions that inhibit one or more cysteine proteases (e.g. caspases or cysteine cathepsins), as well as kits comprising such compounds and compositions. The invention also provides therapeutic met...
|
|
WO/2017/049115A1 |
Methods and system for solid phase peptide synthesis are provided. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. New amino acid residues...
|
|
WO/2017/047572A1 |
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...
|
|
WO/2017/045456A1 |
Disclosed is a cyclic peptide compound of a chemical structure as shown by general formula I, or a pharmaceutically acceptable salt, isomer, racemate, prodrug or solvate thereof. Compared with the positive control (SAHA), the compound ha...
|
|
WO/2017/049165A1 |
The invention provides compounds and their pharmaceutical compositions according to Formula (I) that are useful for inhibiting RNA toxicity, such as in the treatment of myotonic dystrophy type 1, wherein W1, W2, W3, W4, L1, L2, and Cy ar...
|
|
WO/2017/046323A1 |
The invention relates to a peptide, comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin-binding peptide, and (iii) at least one heparin-binding peptide. The invention furthe...
|
|
WO/2017/045063A1 |
The present invention relates to cyclic amino acid molecules, in particular 1,3,4-oxadiazole containing macrocyclic peptides, and a process to produce the same. The process involves the macrocyclization of amino acids or linear peptides....
|
|
WO/2017/044592A1 |
Lipid-conjugated monovalent and bivalent secondary mitochondria derived activator of caspases (Smac) derivatives were synthesized and examined for in vitro and in vivo anticancer activity. Methods for treating cancer with these compounds...
|
|
WO/2017/041403A1 |
The present invention provides a fluorescent probe substrate for determining an activity of dipeptidyl peptidase IV (DPP-IV) and a use thereof. The probe substrate is a C-4 amide derivative of naphthalimides, GPAN, and can be used to det...
|
|
WO/2017/041733A1 |
Provided is a polypeptide that inhibits Aβ protein aggregation of Alzheimer's disease, and an amino acid sequence thereof is Xaa1-Xaa2-Xaa3-Xaa4. Xaa1 and Xaa3 are identical amino acids and selected from I, V or L, Xaa2 is selected from...
|
|
WO/2017/040976A1 |
Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain ...
|
|
WO/2017/040304A1 |
Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin' s lymphoma, d...
|
|
WO/2017/039726A1 |
Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder.
|
|
WO/2017/033055A1 |
The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, d...
|
|
WO/2017/032487A1 |
The present invention relates to compounds such as peptides which act as proteasome inhibitors. The compounds are covalently linked with a signal emitting compound or a precursor thereof, via an ester such as a sulfonic ester group for i...
|
|
WO/2017/030814A1 |
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by ...
|
|
WO/2017/027967A1 |
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...
|
|
WO/2017/031209A1 |
The present disclosure relates to tubulysin derivatives and methods for making the same. The disclosure also relates to the use of such tubulysin derivatives in the preparation of drug conjugates of tubulysins.
|
|
WO/2017/025802A1 |
Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
|
|
WO/2017/021004A1 |
The present invention relates to chromogenic and fluorogenic substrates that can be used for the highly sensitive and selective detection of the activity of serine proteases. The present invention further relates to methods for the detec...
|
|
WO/2017/021904A1 |
The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparatio...
|
|
WO/2017/023907A1 |
The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism o...
|
|
WO/2017/017445A1 |
The invention relates to peptoids, derivatives and analogues thereof, and to methods of chemically synthesising such compounds. The invention relates to mixed peptoids, derivatives and analogues thereof comprising lysine and arginine typ...
|
|
WO/2017/013660A1 |
The present invention discloses a peptide capable of stabilizing mutation-induced GBE1 protein destabilization, conjugates comprising same and uses thereof for the treatment of diseases and disorders associate with glycogen storage.
|
|
WO/2017/013172A1 |
The invention relates to inhibitors for p-glycoprotein, being compounds that comprise or consist of a tripeptide represented by the sequence XAB, wherein X, A, and B are 7amino acids, wherein X can be any amino acid and A and B are basic...
|
